Experiences with
Cyclophosphamide1,159 public posts
Want to take advantage of all our features? Just log in!
or
2025 Spring -Information only - NHS England notification of contingent liability - COVID-19 spring 2025 vaccination programme
Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide